3Papakostas GI, Fava M. Monoamine-based pharmacotherapy// Licinio J, Wong M, eds. Biology of depressio: from novel insights to therapeutic strategies. Weinheim: Wiley-VCH Verlag, 2005 : 87-140.
4Demyttenaere K, Buffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world mental health surveys. JAMA, 2004, 291: 2581-2590.
5Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289:3095-3105.
6Abraham G, Milev R, Smart Lawson J. T3 auglnentation of SSRI resistant depression. J Affect Disord, 2006, 91 (2/3) :211-215.
7Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry, 2003, 64 Suppl 2 : 14-18.
8Hensley PL, Nadiga D, Uhlenhuth EH. Long-term effectiveness of cognitive therapy in major depressive disorder. Depress Anxiety, 2004, 20:1-7.
9UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and metaanalysis. Lancet, 2003, 361:799-808.
10Davison GC, Neal JM, Kring AM. Abnormal Psychology. 9th edition. New York:John Wiley & Sons, Ins. 2004:267-317.
